Recent Developments in Patients with Thalassemia; Comparison of Antioxidant and Cytokine Levels and Possible Measures
Abstract views: 139
/ 
PDF downloads: 69
DOI:
https://doi.org/10.5281/zenodo.10721666Keywords:
Thalassemia, Enzyme, Hemoglobin, Antioxidant, CytokineAbstract
Objective: It is aimed to investigate the underlying causes of thalassemia, which has widespread and negative effects around the world, and to create solutions. For this purpose, antioxidant and anti-inflammatory cytokine levels of thalassemia patients were investigated in our study.
Methods: In our study, experimental and control groups were formed with 40 people in each group. The experimental group consisted of patients with thalassemia followed up at Siirt Training and Research Hospital, and the control group consisted of healthy individuals who came for routine control. After informing the participants in the research and taking their consent, their blood was taken. In serum samples taken from participants in the research, catalase, superoxide dismutase, glutathione reductase, glutathione peroxidase, enzyme activities and malondialdehyde, Vitamins A, E, C, cytokines, total oxidant capacity, and total antioxidant capacity levels were measured. Analyzes were performed on ELISA and HPLC instruments using appropriate kits. The data were analyzed in the IBM SPSS 21.0 statistical package program.
Results: When the results were examined, it was seen that thalassemia patients had lower antioxidant levels and increased anti-inflammatory cytokine levels compared to the control group.
Conclusion: It is possible to say that thalassemia is effective on cytokine and oxidant systems. These harmful effects can be eliminated with food supplements or drugs to be used. We believe that this study will shed light on the preparation of more comprehensive and new treatment protocols in the future.
References
Abdalla, M., Fawzi, M., Al-Maloul, S., El-Banna, N., et al. (2011). Increased oxidative stress and iron over load in Jordanian β-thalassemic children, Hemoglobin, 35, 67-79.
Baysal, E., Indrak, K.G., Bokurt, G.A., Erkalp, A., et al. (1992). The beta-thalassaemia mutations in the population of Cyprus. Br. J. Haematol., 81, 607-609.
Bhagat, S.S., Sarkar, P.D., Suryakar, A.N., Padalkar, R.K., et al. (2013). Attenuation of serum ferritin and iron burden by intake of antioxidants in beta thalassemia majör. Indian J. Physiol. Pharmacol., 57, 189-194.
Dhawan, V., Kumar, K., Marwaha, R.K., Ganguly, N.K. (2005). Antioxidant status in children with homozygous thalassemia. Indian Pediatr., 42, 1141-1145.
Elias, J.A., Freundlich, B., Kern, J.A, et al. (1990). Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest, 97, 1439-1445.
Goldberg, E.K., Ashutosh, L., Fung, E.B. (2022). Nutrition in Thalassemia: A Systematic Review of Deficiency, Relations to Morbidity, and Supplementation Recommendations. J Pediatr Hematol Oncol. 44(1), 1-11.
Ikuta, K., Kohgo, Y., Ohtake, T., Torimoto, Y., et al. (2011). Body iron metabolism and pathophysiology of ironoverload, Int. J. Hematol., 88, 7-15.
Jaafari, Z., Sadidi, N., Zahra Abdolahinia, Z. and Shahesmaeili, A. (2022). Prevalence of Depression among Iranian Patients with Beta-Thalassemia Major: A Systematic Review and Meta-analysis. Iran J Med Sci., 47(1), 15-24.
Karakas, Z., Yilmaz, Y., Celik, D.D., Annayev, A. et al. (2020). The total antioxidant capacity may not be related to bilirubin and uric acid level in patients with beta thalassemia. J Ist Faculty Med, 83(4), 373-377.
Kilic, N., Malhatun, E., Elmali, E., Altan, N. (1988). An investigation into the Effects of the Sulfonylurea Glyburide on Glutathione peroxidase activivity in Streptozotocin-Induced Diabetic Rat Muscle Tissue, Gen Pharmacol, 30, 399-401.
Laksmitawati, D.R., Handayani, S., Udyaningsih-Freisleben, S.K., Kurniati, V., et al. (2003). Iron status and oxidative stress in beta-thalassemia patients in Jakarta, Biofactors, 199, 53-62.
Lal, A. (2020). Challenges in Chronic Transfusion for Patients with Thalassemia. Hematol. Am. Soc. Hematol. Educ. Program, 1, 160–166.
Maryam, M., Hamid, Y., Saeed, S., Ali, A., et al. (2018). Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia majör. Ann. Hematol., 97, 679-684.
Nassima, B., Malika, I., Khadidja, B., Nassima, N., et al. (2015). Oxidative status and plasma lipid profile in b-thalassemia patients, Hemoglobin, 39, 36-41.
Nicod, L.P. (1993). Cytokines: Overview. Thorax, 48, 660-667.
Niki, E. (1993). Antioxidant defenses in eukaryotic cells. In: Poli G, Albano E, Dianzani MU, editors. Free radicals: From basic science to medicine. Basel, Switzerland: Birkhauser Verlag, 365–73.
Oguzhan, O., Huseyin, E., Gokhan, C., Zafer, Y. (2015). Oxidative stress and its impacts on intracellular lipids, proteins and DNA. Journal of Clinicaland Experimental Investigations, 6, 331-336.
Opal, S.M., DePalo, V.A. (2000). Anti-inflammatory cytokines. Chest, 117, 1162-1172.
Origa, R. (2017). Thalassemia. Genet. Med., 19, 609–619.
Ozdem, S., Kupesiz, A., Yesilipek, A. (2008). Plasma homocysteine levels in patients with beta-thalassaemia majör. Scand. J. Clin. Lab. Invest., 68, 134-139.
Pinto, V.M., Forni, G.L. (2020). Management of iron overload in betathalassemia patients: clinical practice update based on case series, Int J Mol Sci, 21, 877-897.
Rahim, A., Tan, A., Mani, R., Kuppusamy, R. (2016). Non-invasive sampling for assessment of oxidative stress and pro-inflammatory cytokine levels in beta-thalassaemia major patients. Revista Română de Medicină de Laborator, 24, 83-92.
Rajendran, P., Nandakumar, N., Rengarajan, T., Palaniswami, R., et al. (2014). Antioxidants and human diseases. Clin. Chim. Acta, 25, 332-347.
Simsek, F., Ozturk, G., Kemahlı, S., Erbas, D. et al.(2005). Oxidant and antioxidant status in beta thalassemia major patients. Journal of Ankara University Faculty of Medicine, 58(1), 34-38.
Sinclair, A.J., Barnett, A.H., Lunec, J. (1990), Free radicals and antioxidant systems in health and diseases. J Hosp Med.,43, 334-44.
Taher, A.T., Weatherall, D.J., Cappellini, M.D. (2018). Thalassaemia, Lancet, 391, 155-167.
Tangvarasittichai, S., Pimanprom, A., Choowet, A., Tangvarasittichai, O. (2013). Association of iron overload and oxidative stress with insulin resistance in transfusion-dependent beta-thalassemia major and beta-thalassemia/HbE patients, Clin. Lab., 59, 861-868.
Tartaglione, I., Carfora, R., Brotto, D., Barillari, M.R., Costa, G., Perrotta, S., Manara, R. (2022). Hearing Loss in Beta-Thalassemia: Systematic Review. J. Clin. Med. 11, 102. https://doi.org/10.3390/jcm11010102.
Williams, T.N., Weatherall, D.J.(2012). World distribution, population genetics, and health burden of the hemoglobinopathies, Cold Spring Harb Perspect Med, .2, a011692.
Yenisey, C., Aktogu, S., Kalenci, S., Erer, F.O. (2006). Proinflammatory cytokines: Are they usefull in differential diagnosis of pleural effusions?. Aegean Medical Journal. 45(1), 19-24.
Zhanga, J., Liub, Z., Chenc, R., Mad, Q., Lyud, Q., Fud, S., Hed, Y., Xiaoa, Z., Luoa, Z., Luoe, J., Wangf, X., Liug, X., Anh, P. and Suna, W. A. (2022). MALDI-TOF mass spectrometry-based haemoglobin chain quantification method for rapid screen of thalassaemia. Annals of Medicine, 54(1), 293-301.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 GEVHER NESIBE JOURNAL OF MEDICAL AND HEALTH SCIENCES
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The journal is licensed under a 